About MPS VI
Maroteaux‐Lamy syndrome (MPS VI) is a progressive, clinically heterogeneous lysosomal storage disorder (LSD) that results from a deficiency in the arylsulfatase B (ASB) enzyme. MPS VI is one of a group of 7 types of LSDs known as mucopolysaccharidosis disorders. An estimated 1100 people worldwide are living with MPS VI.1
In MPS VI, lysosomes deficient in ASB retain excessive amounts of glycosaminoglycans (GAGs), leading to multisystemic organ damage.1,2 MPS VI–related multisystemic abnormalities and significant functional disability are life‐altering.2 While some patients have rapidly progressing disease, others have symptoms that are not recognized until adolescence or later.3
To help patients with MPS VI maintain quality of life, early diagnosis, referral, and treatment are essential.